Medicine:Oculomucocutaneous syndrome
{{Infobox medical condition (new) | name = | synonym = | image = | image_size = | alt = | caption = | pronounce = | specialty = ophthalmology | symptoms = | complications = | onset = | duration = | types = | causes = | risks = | diagnosis = | differential = | prevention = | treatment = | medication = | prognosis = | frequency = | deaths = Oculomucocutaneous syndrome is characterized by keratoconjunctivitis sicca (dry eyes) and the resulting scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva.[1] It is a drug side effect observed in practolol and eperisone. It is speculated that antibodies against drug metabolites cause the syndrome.[2]
References
- ↑ Wright, P (Mar 15, 1975). "Untoward effects associated with practolol administration: oculomucocutaneous syndrome.". British Medical Journal 1 (5958): 595–8. doi:10.1136/bmj.1.5958.595. PMID 1125623.
- ↑ Amos, HE; Lake, BG; Artis, J (Feb 18, 1978). "Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome.". British Medical Journal 1 (6110): 402–4. doi:10.1136/bmj.1.6110.402. PMID 146533.
Original source: https://en.wikipedia.org/wiki/Oculomucocutaneous syndrome.
Read more |